601 ORAL Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis

首页> 外文期刊>European Journal of Cancer Supplements >601 ORAL Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis

【24h】

601 ORAL Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis

机译：601口服5-氟尿嘧啶/亚叶酸加奥沙利铂（FUFOX）与卡培他滨加奥沙利铂（CAPOX）作为转移性结直肠癌（MCRC）的一线治疗：安全性和有效性分析的结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. [J] . Rothenberg ML, Cox JV, Butts C, Annals of oncology: official journal of the European Society for Medical Oncology . 2008,第10期

机译：卡培他滨加奥沙利铂（XELOX）与5-氟尿嘧啶/亚叶酸加奥沙利铂（FOLFOX-4）作为转移性结直肠癌的二线治疗：一项III期非劣效性随机研究。
2. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study [J] . M. L. Rothenberg1 J. V. Cox2 C. Butts3 M. Navarro4 Y.-J. Bang5 R. Goel6 S. Gollins7 L. L. Siu8 S. Laguerre9 and D. Cunningham10 Annals of Oncology . 2008,第10期

机译：卡培他滨加奥沙利铂（XELOX）与5-氟尿嘧啶/亚叶酸加奥沙利铂（FOLFOX-4）作为转移性结直肠癌的二线治疗：一项随机的非III期临床研究
3. 636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：636 POSTER卡培他滨（X）加奥沙利铂（XELOX）与输注5-FU / LV加奥沙利铂（FOLFOX-6）的III期临床研究在转移性结直肠癌患者（pts）的一线治疗中的初步安全性发现（ MCRC）
4. Bevacizumab with 5-fluorouracil leucovorin and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis [O] . Tomas Buchler, Tomas Pavlik, Bohuslav Melichar, 2014

机译：贝伐单抗联合5-氟尿嘧啶亚叶酸和奥沙利铂与贝伐单抗联合卡培他滨和奥沙利铂治疗转移性结直肠癌：基于登记的大型队列研究结果
5. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial [O] . Comella P, Massidda B, Filippelli G, 2005

机译：奥沙利铂加大剂量亚叶酸和5-氟尿嘧啶静脉注射静脉推注（OXAFAFU）与伊立替康加大剂量亚叶酸和5-氟尿嘧啶静脉内注射转移性结直肠癌患者的大剂量推注（IRIFAFU）：意大利南部合作肿瘤小组III期试验

601 ORAL Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis

著录项

相似文献

相关主题

期刊订阅